fluorobenzenes has been researched along with Basal Ganglia Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carr, AA; Dudley, MW; Gittos, MW; Kehne, JH; Moser, P; Palfreyman, MG; Schmidt, CJ; Sorensen, SM | 1 |
| Angst, J; Frei, M | 1 |
1 trial(s) available for fluorobenzenes and Basal Ganglia Diseases
| Article | Year |
|---|---|
[The depot neuroleptic agent fluspirilene (author's transl)].
Topics: Basal Ganglia Diseases; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Female; Fluorobenzenes; Fluphenazine; Heart Rate; Humans; Injections, Intramuscular; Male; Parkinson Disease, Secondary; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Spiro Compounds; Time Factors; Tranquilizing Agents | 1973 |
1 other study(ies) available for fluorobenzenes and Basal Ganglia Diseases
| Article | Year |
|---|---|
Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.
Topics: Animals; Basal Ganglia Diseases; Behavior, Animal; Dopamine; Electrophysiology; Fluorobenzenes; Indoles; Male; Mice; Microdialysis; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Piperidines; Quinolizines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Antagonists | 1993 |